AI Article Synopsis
- The study aimed to investigate if certain gene polymorphisms related to fibrinolysis affect thrombotic events in patients with antiphospholipid antibodies (aPL).
- Researchers analyzed gene variants of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) in a sample of Japanese and British patients with aPL.
- The findings showed no significant differences in gene polymorphism frequencies between patients and controls, nor a correlation with clinical symptoms of antiphospholipid syndrome, suggesting these polymorphisms do not impact thrombosis risk.
Article Abstract
Objective: Impaired fibrinolytical outcomes may be one of the pathogenic factors for thrombotic events in patients with antiphospholipid antibodies (aPL). We investigated the consequences of the gene polymorphisms of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) in patients positive for aPL.
Methods: Seventy-seven Japanese and 82 British patients with aPL were examined for Alu-repeat insertion (I)/deletion (D) polymorphism of the tPA gene by polymerase chain reaction (PCR), and 4G/5G polymorphism in the PAI-1 promoter gene by site-directed mutagenesis-PCR and restriction fragment length polymorphism analysis. Correlations between these polymorphisms and clinical symptoms of antiphospholipid syndrome (APS) (arterial thrombosis, venous thrombosis, miscarriage) were analyzed.
Results: Significant differences in the allele frequencies of these genes did not exist between patients and controls. There was no significant correlation between these gene polymorphisms and clinical symptoms of APS in patients with aPL.
Conclusion: Polymorphisms of the tPA or PAI-1 genes probably do not significantly influence the risk of anerial thrombosis, venous thrombosis, or pregnancy morbidity in patients with aPL.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Acute ischemic stroke treatment].
Med Klin Intensivmed Notfmed
January 2025
Neurologische Klinik, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland.
Intravenous thrombolysis (IVT) and endovascular therapy (EVT) are the cornerstones of acute ischemic stroke treatment. While IVT has been an integral part of acute therapy since the mid-1990s, EVT has evolved as one of the most effective treatments in medicine over the past decade. Traditionally, systemic thrombolysis has been performed with alteplase (rtPA).
View Article and Find Full Text PDFNeurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers.
Prog Neuropsychopharmacol Biol Psychiatry
January 2025
Department of Psychiatry, University Medical Center Groningen, Groningen, the Netherlands.
Psilocybin represents a novel therapeutic approach for individuals with major depressive disorder (MDD) who do not respond to conventional antidepressant treatment. Investigating the influence of psilocybin on the pathophysiological processes involved in MDD could enhance our neurobiological understanding of the presumed antidepressant action mechanism. This systematic review aims to summarize the results of human studies investigating changes in blood-based biomarkers of MDD to guide future research on potentially relevant analytes that could be monitored in clinical trials.
View Article and Find Full Text PDFAssociations of CAIDE dementia risk score with glucose and lipid‐related metabolic blood biomarkers in the FINGER study participants.
Alzheimers Dement
December 2024
Division of clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden
Background: The Cardiovascular risk factors, aging, and dementia (CAIDE) risk score is a validated tool estimating dementia risk. We investigated the association of CAIDE score with 12 markers of glucose and lipid metabolism, in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) participants.
Methods: The FINGER trial had 1260 participants, aged 60–77 years, with a CAIDE score ≥6, without substantial cognitive impairment.
Intracellular adhesion molecule 1 in prodromal Alzheimer’s disease.
Alzheimers Dement
December 2024
Department of Neurology, University of Cologne, Medical Faculty, Cologne, Germany
Background: Age represents the predominant risk factor for Alzheimer's disease (AD) dementia. Nevertheless, not every elderly individual undergoes age‐related processes that inevitably lead to dementia. The aging process is characterized by cellular senescence, manifesting as morphological changes and the secretion of immune signaling mediators linked to systemic low‐grade inflammation.
View Article and Find Full Text PDFSpontaneous Spinal Cord Infarction in a Young Patient: An Overview of Clinical Features and Management.
Stroke
January 2025
Department of Neurology, New York University Grossman School of Medicine, NY. (C.C., H.A., A.K., S.M.K.).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!